What were the key takeaways from Vericel’s earnings call?

What were the key takeaways from Vericel's earnings call?

What does Vericel do and what are its main business segments?

What is Vericel's latest dividend and current dividend yield?

Did Vericel beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Vericel next quarter?

What is Vericel's gross profit margin?

What guidance did Vericel's management provide for the next earnings period?

- **Record Q4 Growth**: Total revenue $92.9 million (+23% YoY), MACI $84.1 million (+23% YoY), and 79% gross margin.
- **Strategic Expansion**: 30% MACI sales force increase, MACI Arthro adoption by 1,000 surgeons, and U.K. launch in 2027.
- **2026 Outlook**: $316-$326 million revenue target, 75% gross margin, and $220 million OpEx.
- **Key Drivers**: MACI Arthro for small condyle defects, Ankle MASCOT trial, and U.S. sales force productivity recovery.
- **Financial Strength**: $200 million cash, 59% YoY net income growth, and $52 million operating cash flow.

**【Management Opening Remarks】**
- Eric Burns introduced the call participants and highlighted the availability of the press release and presentation. He emphasized forward-looking statements and the company's financial health with $200 million in cash and no debt.

**【CEO Commentary】**
- **Q4 2025 Performance**: Record revenue of $92.9 million (+23% YoY), MACI revenue of $84.1 million (+23% YoY), and gross margin of 79%. Full-year revenue reached $276.3 million (+21% YoY).
- **Strategic Initiatives**: MACI sales force expansion (30% increase), MACI Arthro adoption (1,000 trained surgeons), and Ankle MASCOT clinical study initiation. MACI Ankle launch in the U.K. planned for 2027.
- **MACI Growth Drivers**: 20,000+ patients treated, 95% prior authorization approval rate, and 24% CAGR since 2017.
- **2026 Outlook**: Focus on sales force productivity, MACI Arthro for small condyle defects, and MACI Ankle expansion.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: GAAP net income of $16.5 million (+59% YoY), adjusted EBITDA of $37 million (40% margin), and $52 million operating cash flow.
- **2026 Guidance**: Total revenue $316-$326 million (MACI: $280-$286 million; Burn Care: $36-$40 million). Gross margin 75%, adjusted EBITDA margin 27%, and OpEx $220 million.
- **Key Drivers**: MACI sales force expansion, MACI Arthro adoption, and Ankle MASCOT clinical trial expenses.

**【Q&A Highlights】**
- **MACI Growth Balance**: 20%+ YoY growth driven by price and volume, with Q4 2025 volume-driven momentum.
- **Sales Force Expansion**: 30 new reps added in Q4 2025, targeting 2026 productivity return to 2025 levels.
- **MACI Arthro Impact**: Trained surgeons show 50%+ biopsy growth, with higher conversion rates for implanters.
- **Free Cash Flow**: Adjusted EBITDA a proxy for operating cash flow, with low CapEx post-facility completion.
- **BARDA RFP**: Potential NexoBrid revenue from strategic stockpiling, with 2026 award possibility.
- **U.K. Launch**: Direct commercialization in 12 centers of excellence, targeting 2027 launch.


Vericel Corporation(VCEL)-20260226-2025 Q4 Earnings call transcript

- **MACI Dominance**: Q3 revenue up 25% YoY to $55.7M, driven by 800+ trained surgeons and MACI Arthro adoption. Q4 guidance $82-84M, 2025 full year +20%.
- **Profit Surge**: Adjusted EBITDA $17M (25% margin), free cash flow $20M. 2029 targets: 75%+ gross margin, 35%+ EBITDA.
- **Growth Catalysts**: MACI Ankle study to begin Q4, U.K. launch 2027, and 25 new sales reps on track for Q4 completion.
- **Burn Care Volatility**: NexoBrid Q3 high, but BARDA contract uncertain. Epicel Q4 expected stable.

**【CEO Summary Section】**
- **Record Q3 Revenue**: Total revenue of $67.5M, with MACI up 25% YoY to $55.7M, driven by MACI Arthro adoption and biopsy growth. Burn Care revenue reached $11.8M, highest quarterly since launch.
- **MACI Arthro Momentum**: 800+ trained surgeons, with biopsy and implant growth rates exceeding untrained surgeons. Early data shows faster recovery times and higher conversion rates for trained surgeons.
- **Future Growth Initiatives**: Phase III MACI Ankle study to begin Q4 2025, targeting U.S. launch in 2027. U.K. expansion via mutual recognition procedure, with potential launch in H1 2027.
- **Sales Force Expansion**: 25 new reps on track to complete Q4, supporting Q4 volume growth and 2026+ expansion.

**【CFO Financial Commentary】**
- **Profitability**: GAAP net income $5.1M, adjusted EBITDA $17M (25% margin), up 70% YoY. Free cash flow $20M, ending Q3 with $185M cash.
- **Guidance**: Full year 2025 revenue $272-276M (MACI $237.5-239.5M, +20% YoY). Q4 MACI $82-84M, Burn Care $6.5-8.5M. Gross margin 74%, adjusted EBITDA 26%.
- **2026 Outlook**: MACI growth expected to accelerate, with gross margin >77% and EBITDA margin >40%. Long-term targets: 75%+ gross margin, 35%+ EBITDA by 2029.

**【Q&A Highlights】**
- **MACI Arthro Cannibalization**: No decline in core MACI; Arthro targets smaller defects (1-4cm²). 1/3 of trained surgeons are new MACI users, 1/3 condyle-only, 1/3 mixed.
- **Biopsy Trends**: Q3 biopsies highest on record, with October setting new monthly high. Q4 biopsy growth supports $82-84M MACI guidance.
- **Burn Care Volatility**: NexoBrid Q3 revenue $1.5M (+38% YoY), but BARDA contract uncertain. Epicel Q4 expected to match 2024 levels.
- **MACI Pricing**: Mid-single-digit price increases sustainable due to medical benefit reimbursement and high-tech product positioning.

Vericel Corporation (VCEL) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 revenue up 20% YoY to $63.2M, driven by MACI (21% YoY) and Burn Care rebound. Gross margin at 74%, highest since Q4 2024.
- **MACI Arthro Momentum**: 600 trained surgeons, 40% growth in small femoral condyle defects, and 100+ biopsies from new arthro-only surgeons.
- **Burn Care Reset**: Epicel biopsies up 40% YoY but Q2 revenue growth limited by cancellations. Updated guidance of $10M/Q4, though team aims to outperform.
- **MACI Ankle Expansion**: IND-cleared Phase III trial to start Q3, targeting $1B market.
- **Cash Strength**: $164M cash, no debt, with operating cash flow of $8.2M in Q2.

**【CEO Summary Section】**
- Q2 total revenue grew 20% YoY to $63.2M, driven by MACI (21% YoY growth) and strong Burn Care rebound. Gross margin expanded 400bps to 74%, and adjusted EBITDA rose 112% to $13.4M.
- MACI Arthro trained surgeons reached 600 by end-July, with biopsy growth outpacing implants in H1. Q2 MACI revenue hit $53.5M, up 21% YoY, with 40% growth in small femoral condyle defects.
- Burn Care showed resilience: Epicel biopsies up 40% YoY, NexoBrid orders at record levels. New MACI sales force expansion to 100 territories by end-2025 to support H2 volume.

**【CFO Financial Commentary】**
- Q2 GAAP net loss narrowed to $0.6M (-$4.7M YoY), with operating cash flow of $8.2M and $164M cash on hand.
- Operating expenses rose 14% YoY to $48.6M due to headcount and new facility costs. Full-year guidance reaffirmed: gross margin 74%, EBITDA margin 26%.
- Updated Burn Care guidance: $10M/Q4 starting Q3, though internal expectations remain higher. BARDA RFP potential for NexoBrid in Q4.

**【Q&A Key Highlights】**
- **MACI Implant Timing**: Biopsy-implant convergence expected in H2, with Q2 biopsy growth (40% YoY) outpacing implants. Q3 MACI revenue guided to $54-55M.
- **Epicel Challenges**: 40% biopsy growth vs. 11% revenue growth due to patient cancellations. Guidance reset to $10M/Q4 but team targeting outperformance.
- **MACI Ankle Trial**: Phase III study to start Q3 with 300 patients, targeting $1B addressable market.
- **International Expansion**: Europe prioritized, with potential 2027-2028 launches via mutual recognition pathways.
- **BARDA RFP**: 2,750 units procurement in Q4 2025-Q3 2026, with management contract potential. Revenue timing and amounts TBD post-selection.

Vericel Corporation (VCEL) Q2 2025 Earnings Call Transcript

- **MACI Arthro Breakthrough**: 400+ trained surgeons driving >30% biopsy growth, with Q2 MACI revenue up 22%–24% YoY. Trochlea defects unlock $10M+ annual market.
- **Profit Margin Expansion**: Full-year adjusted EBITDA margin raised to 26% (from 24%), supported by cost control and MACI expansion.
- **Burn Care Recovery**: NexoBrid up 207% YoY, Epicel Q2 grafts exceed Q1, positioning burn care for H2 strength.
- **Tariff Resilience**: U.S.-based manufacturing limits impact, with 2025 gross margin guidance unchanged at 75%.


**【CEO Summary Section】**
- **Record Q1 Revenue**: Total revenue reached $52.6 million, driven by MACI ($46.3 million, +15% YoY) and strong NexoBrid growth (+207% YoY). MACI Arthro trained surgeons showed biopsy growth >30% YoY, with 400+ surgeons trained as of Q1.
- **MACI Arthro Momentum**: Trochlea defect cases (10,000+ annual patients) are emerging as a new growth driver, with MACI Arthro implants expected to accelerate in H2 2025. Q2 MACI revenue guidance: +22% to +24% YoY.
- **Burn Care Recovery**: NexoBrid revenue up 31% QoQ, while Epicel grafts in Q2 exceeded Q1 volume, driven by delayed Q1 surgeries.
- **Guidance Update**: Full-year revenue growth raised to 20%–23%, with adjusted EBITDA margin guidance increased to 26% (from 24%) due to cost control and MACI expansion.

**【CFO Financial Commentary】**
- **Gross Margin Stability**: Q1 gross margin held steady at 69%, despite lower Epicel revenue. Q2 gross margin expected to improve to low 70% due to higher MACI and NexoBrid volumes.
- **Operating Expenses**: Q1 operating expenses rose to $49.1 million (+15% YoY) due to facility costs and MACI Tech transfer. Full-year expenses remain flat, with MACI sales force expansion planned for H2.
- **Cash Flow**: Generated $6.6 million in operating cash flow, ending Q1 with $162 million in cash, no debt. Tariffs expected to have negligible impact on 2025 margins.

**【Q&A Key Themes】**
- **MACI Arthro Surgeon Training**: 400+ trained surgeons (vs. 200+ at MACI launch in 2017), with biopsies from trained surgeons up >30% YoY. MACI Ankle Phase III study on track for H2 2025 initiation.
- **Sales Force Expansion**: Limited 2025 expansion focused on high-volume territories, with full-scale growth planned for 2026 to support MACI Arthro adoption.
- **Epicel Volatility**: Q1 grafts impacted by patient health issues, but Q2 grafts already exceed Q1. Burn care franchise expected to stabilize in H2.
- **International Strategy**: MACI international expansion under evaluation, with U.S. manufacturing shielding from tariffs.


Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript

- **Record 2024 Performance**: $237M revenue (+20%), MACI up 20%, Burn Care up 22%, gross margin 73%.
- **MACI Arthro Momentum**: 250 surgeons trained, biopsies from new segments, Q4 MACI revenue +53% QoQ.
- **Profitability Expansion**: 2024 adjusted EBITDA $53.4M (+58%), Q4 margin 40%.
- **2025 Guidance**: 20-23% revenue growth, 73-74% gross margin, 25-26% EBITDA margin.
- **Key Initiatives**: MACI Ankle IND in H1 2025, OUS manufacturing in 2026, NexoBrid 2025 revenue $3-4M.

**【CEO Summary Section】**
- Vericel delivered record 2024 revenue of $237.2 million (+20% YoY), with MACI franchise revenue up 20% to $197.3 million and Burn Care up 22% to $39.9 million.
- Q4 revenue hit $75.4 million, the highest quarterly total in company history, driven by MACI Q4 revenue of $68.3 million (+21% YoY, +53% QoQ).
- MACI Arthro launch shows early momentum: 250 surgeons trained to date, biopsies from new surgeon segments, and cases completed in all target segments.
- Gross margin expanded to 73% for the year (78% in Q4), with adjusted EBITDA margin at 23% (40% in Q4).
- 2025 guidance: Revenue growth 20-23%, gross margin 73-74%, adjusted EBITDA margin 25-26%.

**【CFO Financial Commentary】**
- Full year GAAP net income of $10.4 million ($0.20 EPS) vs. loss of $3.2 million in 2023.
- Q4 net income $19.8 million ($0.38 EPS), up 52% YoY.
- Operating cash flow $58.2 million, ending with $167 million in cash (no debt).
- 2025 CapEx expected to drop to $15-20 million after H1 equipment purchases.

**【Q&A Highlights】**
- MACI Arthro: 250 surgeons trained, biopsy growth rate for trained surgeons 3x higher than untrained, potential to boost MACI utilization beyond core 20% growth.
- NexoBrid: Q4 hospital orders +42% QoQ, 2025 revenue target $3-4 million (vs. $3.3 million in 2024).
- MACI Ankle: IND submission expected H1 2025, Phase III study to begin H2 2025 with ~200 patients.
- International expansion: New facility in 2026 to enable OUS manufacturing, initial focus on Europe and South America.
- Burn Care: Epicel 2025 growth ~7-8% driven by price, NexoBrid to drive new account penetration.

Actual												-0.1	-0.18	0.08	0.25	-0.07	-0.08	-0.11	0.09	-0.15	-0.19	-0.14	0.12	-0.16	-0.11	-0.08	0.26	-0.08	-0.1	-0.02	0.38	-0.23	-0.01	0.1	0.45
Forecast												-0.0817	-0.2067	-0.0243	0.2028	-0.0413	-0.0838	-0.0283	0.143	-0.1173	-0.1222	-0.1017	0.036	-0.1533	-0.1518	-0.1212	0.1737	-0.1102	-0.0929	-0.0482	0.3196	-0.1236	-0.0317	-0.0063	0.4092
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-22.40%	+12.92%	+429.22%	+23.27%	-69.49%	+4.53%	-288.69%	-37.06%	-27.88%	-55.48%	-37.66%	+233.33%	-4.37%	+27.54%	+33.99%	+49.68%	+27.40%	-7.64%	+58.51%	+18.90%	-86.08%	+68.45%	+1687.30%	+9.97%

VCEL

VCEL fundamentals

VCEL Q4 2025 Earnings

Earnings Call

You can ask Aime

VCEL

VCEL fundamentals

VCEL Q4 2025 Earnings

Earnings Call

VCEL Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

VCEL Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

VCEL Earnings Call Summary for Q2/20258:30 AM on Jul 31, 2025

VCEL Earnings Call Summary for Q1/20258:30 AM on May 8, 2025

VCEL Earnings Call Summary for Q4/20248:30 AM on Feb 27, 2025

You can ask Aime